Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 4
1976 3
1977 2
1978 4
1979 1
1980 2
1981 6
1982 2
1983 3
1984 3
1985 4
1986 5
1987 1
1988 5
1989 9
1990 7
1991 18
1992 15
1993 14
1994 17
1995 20
1996 16
1997 25
1998 28
1999 29
2000 37
2001 39
2002 58
2003 64
2004 65
2005 66
2006 42
2007 52
2008 63
2009 74
2010 61
2011 82
2012 90
2013 104
2014 96
2015 97
2016 123
2017 103
2018 123
2019 88
2020 103
2021 112
2022 125
2023 121
2024 55

Text availability

Article attribute

Article type

Publication date

Search Results

2,062 results

Results by year

Filters applied: . Clear all
Page 1
Complete integration of carbene-transfer chemistry into biosynthesis.
Huang J, Quest A, Cruz-Morales P, Deng K, Pereira JH, Van Cura D, Kakumanu R, Baidoo EEK, Dan Q, Chen Y, Petzold CJ, Northen TR, Adams PD, Clark DS, Balskus EP, Hartwig JF, Mukhopadhyay A, Keasling JD. Huang J, et al. Among authors: mukhopadhyay a. Nature. 2023 May;617(7960):403-408. doi: 10.1038/s41586-023-06027-2. Epub 2023 May 3. Nature. 2023. PMID: 37138074
Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
Banerjee M, Maisnam I, Pal R, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. Eur Heart J. 2023 Oct 1;44(37):3686-3696. doi: 10.1093/eurheartj/ehad522. Eur Heart J. 2023. PMID: 37605637
HR 0.98; 95% CI 0.86-1.13; P-interaction = .034). SGLT2i reduced all-cause mortality (P-interaction = .27) and adverse renal endpoints regardless of MRA use (P-interaction = .73) despite a higher risk of volume depletion with concomitant MRAs (P-intera …
HR 0.98; 95% CI 0.86-1.13; P-interaction = .034). SGLT2i reduced all-cause mortality (P-interaction = .27) and adverse renal e …
Calcium Signaling Commands Phagosome Maturation Process.
Pradhan G, Raj Abraham P, Shrivastava R, Mukhopadhyay S. Pradhan G, et al. Among authors: mukhopadhyay s. Int Rev Immunol. 2019;38(2):57-69. doi: 10.1080/08830185.2019.1592169. Int Rev Immunol. 2019. PMID: 31117900 Review.
Phagosome-lysosome (P-L) fusion is one of the central immune-effector responses of host. ...Some of the intracellular pathogens have acquired the strategies to modulate Ca(2+) associated pathways to block P-L fusion process. In this review we have described the mech …
Phagosome-lysosome (P-L) fusion is one of the central immune-effector responses of host. ...Some of the intracellular pathogens have …
SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
Banerjee M, Pal R, Nair K, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. Indian Heart J. 2023 Mar-Apr;75(2):122-127. doi: 10.1016/j.ihj.2023.03.003. Epub 2023 Mar 11. Indian Heart J. 2023. PMID: 36914068 Free PMC article.

Pooled analysis showed that compared to placebo, SGLT2i use was significantly associated with improved CVD/HHF outcomes in HFmrEF/HFpEF (pooled HR 0.80, 95% CI: 0.74, 0.86, p < 0.001, I(2) = 0%). When separately analyzed, benefits of SGLT2i remained significant across H

…
Pooled analysis showed that compared to placebo, SGLT2i use was significantly associated with improved CVD/HHF outcomes in HFmrEF/HFpEF (poo …
Lipid Profile in Infant.
Kumar A, Pandit K, Chatterjee P, Mukhopadhyay P, Ghosh S. Kumar A, et al. Among authors: mukhopadhyay p. Indian J Endocrinol Metab. 2021 Jan-Feb;25(1):20-22. doi: 10.4103/ijem.IJEM_396_20. Epub 2021 Jul 21. Indian J Endocrinol Metab. 2021. PMID: 34386389 Free PMC article.
The total cholesterol and LDL-cholesterol measured in 4 and >4 weeks of age groups were statistically not different (total cholesterol 125.0 30.1 mg/dl vs 127.4 23.4 mg/dl, P = 0.727, and LDL-cholesterol 66.0 19.2 mg/dl vs 75.4 21.2 mg/dl, P = 0.780). However, th …
The total cholesterol and LDL-cholesterol measured in 4 and >4 weeks of age groups were statistically not different (total cholesterol 12 …
Impact of Pulmonary Hypertension in Patients With Hypertrophic Cardiomyopathy Presented With Cardiogenic Shock/Acute Decompensated Heart Failure.
Chakraborty S, Das SK, Lorente-Ros M, Patel N, Hajra A, Bandyopadhyay D, Malik A, Goel A, Mukhopadhyay S, Aronow WS. Chakraborty S, et al. Among authors: mukhopadhyay s. Curr Probl Cardiol. 2022 Sep;47(9):101251. doi: 10.1016/j.cpcardiol.2022.101251. Epub 2022 May 13. Curr Probl Cardiol. 2022. PMID: 35577078 Review.

Patients with PH had a higher prevalence of chronic kidney disease (P < 0.001), anemia (P < 0.001), coagulopathy (P < 0.001), atrial fibrillation (P = 0.031), and valvular disease (P < 0.001) (Table 1). The primary outcome (all-cause

…

Patients with PH had a higher prevalence of chronic kidney disease (P < 0.001), anemia (P < 0.001), coagulopathy (P

…
GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis.
Banerjee M, Pal R, Maisnam I, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. Diabetes Metab Syndr. 2024 Jan;18(1):102943. doi: 10.1016/j.dsx.2024.102943. Epub 2024 Jan 5. Diabetes Metab Syndr. 2024. PMID: 38211482 Review.

Randomization to GLP-1 RA treatment versus placebo was associated with reduced noncardiovascular mortality (RR = 0.90; 95%CI: 0.81-0.99; I(2) = 0 %; p < 0.05), consistent with their effects on cardiovascular mortality (RR = 0.88; 95%CI: 0.81-0.95; I(2) = 0 %; p &

…
Randomization to GLP-1 RA treatment versus placebo was associated with reduced noncardiovascular mortality (RR = 0.90; 95%CI: 0.81-0.99; I(2 …
Elucidation of structure-function relationships in Methanocaldococcus jannaschii RNase P, a multi-subunit catalytic ribonucleoprotein.
Phan HD, Norris AS, Du C, Stachowski K, Khairunisa BH, Sidharthan V, Mukhopadhyay B, Foster MP, Wysocki VH, Gopalan V. Phan HD, et al. Among authors: mukhopadhyay b. Nucleic Acids Res. 2022 Aug 12;50(14):8154-8167. doi: 10.1093/nar/gkac595. Nucleic Acids Res. 2022. PMID: 35848927 Free PMC article.
RNase P is a ribonucleoprotein (RNP) that catalyzes removal of the 5' leader from precursor tRNAs in all domains of life. A recent cryo-EM study of Methanocaldococcus jannaschii (Mja) RNase P produced a model at 4.6-A resolution in a dimeric configuration, with each …
RNase P is a ribonucleoprotein (RNP) that catalyzes removal of the 5' leader from precursor tRNAs in all domains of life. A recent cr …
Engineering isoprenoids production in metabolically versatile microbial host Pseudomonas putida.
Wang X, Baidoo EEK, Kakumanu R, Xie S, Mukhopadhyay A, Lee TS. Wang X, et al. Among authors: mukhopadhyay a. Biotechnol Biofuels Bioprod. 2022 Dec 12;15(1):137. doi: 10.1186/s13068-022-02235-6. Biotechnol Biofuels Bioprod. 2022. PMID: 36510293 Free PMC article.
As P. putida can natively consume isoprenol, we investigated how to prevent this self-consumption. ...We also showed that the engineered P. putida strain can produce isoprenol using aromatic substrates such as p-coumarate as the sole carbon source, and this r …
As P. putida can natively consume isoprenol, we investigated how to prevent this self-consumption. ...We also showed that the enginee …
Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma.
Riner AN, Herremans KM, Vudatha V, Han S, Qu X, Liu J, Mukhopadhyay N, Freudenberger DC, George TJ, Judge SM, Judge AR, Hughes SJ, Trevino JG. Riner AN, et al. Among authors: mukhopadhyay n. J Cachexia Sarcopenia Muscle. 2024 Feb;15(1):149-158. doi: 10.1002/jcsm.13390. Epub 2023 Dec 20. J Cachexia Sarcopenia Muscle. 2024. PMID: 38123146 Free PMC article.
BMI (P = 0.642), SMI (P = 0.738) and MRA (P = 0.478) were similar between groups. ...Survival differed by tumour location (P = 0.014) with numerically higher median overall survival with distal tumours (11.1 vs. 21.8 months; P = 0.066). ...
BMI (P = 0.642), SMI (P = 0.738) and MRA (P = 0.478) were similar between groups. ...Survival differed by tumour locati …
2,062 results